Complement inhibition as a therapeutic strategy in retinal disorders

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–116.
   PubMed Web of Science ®Google Scholar
• Df M, Mg M, Sl F, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–1398.
   PubMed Web of Science ®Google Scholar
• Danobeitia JS, Djamali A, Fernandez LA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair. 2014;7:16.
   PubMedGoogle Scholar
• Seddon JM, George S, Rosner B, et al. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol. 2005;123:774–782.
   PubMed Web of Science ®Google Scholar
• Bok D. Evidence for an inflammatory process in age-related macular degeneration gains new support. Proc Natl Acad Sci U S A. 2005;102:7053–7054.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Miskala PH, Green WR, et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no7. Arch Ophthalmol. 2005; 123:914–921.
   PubMedGoogle Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385–389.
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419–421.
   PubMed Web of Science ®Google Scholar
• Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol. 2013;13:438–451.
   PubMed Web of Science ®Google Scholar
• Khandhadia S, Cipriani V, Yates JR, et al. Age-related macular degeneration and the complement system. Immunobiology. 2012;217:127–146.
   PubMed Web of Science ®Google Scholar
• van Lookeren Campagne M, LeCouter J, Yaspan BL, et al. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014;232:151–164.
   PubMed Web of Science ®Google Scholar
• Den Hollander AI, de Jong EK. Highly penetrant alleles in age-related macular degeneration. Cold Spring Harb Perspect Med. 2014;5:a017202.
   PubMed Web of Science ®Google Scholar
• Kavanagh D, Yu Y, Schramm EC, et al. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet. 2015;24:3861–3870.
   PubMed Web of Science ®Google Scholar
• van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet. 2013;45:813–817.
   PubMed Web of Science ®Google Scholar
• Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103:2328–2333.
   PubMed Web of Science ®Google Scholar
• Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye (Lond). 2001;15:390–395.
   PubMed Web of Science ®Google Scholar
• Johnson LV, Leitner WP, Staples MK, et al. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887–896.
   PubMed Web of Science ®Google Scholar
• Lv J, Dl F, Cd B, et al. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108:18277–18282.
   PubMed Web of Science ®Google Scholar
• Francis PJ, Schultz DW, Hamon S, et al. Haplotypes in the complement factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration. PLoS One. 2007;2:e1197.
   PubMed Web of Science ®Google Scholar
• Mullins RF, Schoo DP, Sohn EH, et al. The membrane attack complex in aging human choriocapillaris: relationship to macular degeneration and choroidal thinning. Am J Pathol. 2014;184:3142–3153.
   PubMed Web of Science ®Google Scholar
• Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994;179:985–992.
   PubMed Web of Science ®Google Scholar
• Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. Immunol. 1990;144:3478–3483.
   Web of Science ®Google Scholar
• Lyzogubov VV, Bora PS, Wu X, et al. The complement regulatory protein CD46 deficient mouse spontaneously develops dry-type age-related macular degeneration-like phenotype. Am J Pathol. 2016;186:2088–2104.
   PubMed Web of Science ®Google Scholar
• Yaspan BL, Williams DF, Holz FG, et al. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med. 2017;9:eaaf1443.
   PubMed Web of Science ®Google Scholar
• Cao S, Wang JC, Gao J, et al. CFH Y402H polymorphism and the complement activation product C5a: effects on NF-kappaB activation and inflammasome gene regulation. Br J Ophthalmol. 2016;100:713–718.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Schmitz-Valckenberg S, Boyer D, et al. Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration: the GATE study. Am J Ophthalmol. 2015;160:1226–1234.
   PubMed Web of Science ®Google Scholar
• Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of Lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri Phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136:666–677.
   PubMed Web of Science ®Google Scholar
• Lenier S APL-2 slows growth of GA in phase II safety and efficacy trial. Available from: http://www.modernretina.com/amd/apl-2-slows-growth-ga-phase-ii-safety-and-efficacy-trial
   Google Scholar
• Introducing two new phase 3 trials in geographic atrophy (GA). Available from: https://gastudy.com/
   Google Scholar
• Furfine E. Discovery and planned optimization of a complement factor C3-inactivating alterase, CB-2782. Available from: https://iovs.arvojournals.org/article.aspx?articleid=2688983&resultClick=1.
   Google Scholar
• Dugel PU A phase I single ascending dose study of an intravitreal (IVT) anti-C5 monoclonal antibody (LFG316) in patients with advanced age related macular degeneration (AMD). Presented at the Association for Research in Vision and Ophthalmology annual meeting. 2014.
   Google Scholar
• Anti-complement C5 monotherapy ineffective in reducing geographic atrophy lesion size. 2016. Available from: https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7Bb24258c2-0a16-425c-9476-a591485d3cf6%7D/anti-complement-c5-monotherapy-ineffective-in-reducing-geographic-atrophy-lesion-size
   Google Scholar
• Gallemore RP, Elman MJ, Milton M, et al. A proof of concept study of intravitreal (IVT) LFG316 in patients with neovascular age related macular degeneration (nAMD). Presented at the Association of Research in Vision and Ophthalmology annual meeting. 2016.
   Google Scholar
• Berchuck JE, Yang P, Toimil BA, et al. All-trans-retinal sensitizes human RPE cells to alternative complement pathway-induced cell death. Invest Ophthalmol Vis Sci. 2013;54:2669–2677.
   PubMed Web of Science ®Google Scholar
• Radu RA, Hu J, Yuan Q, et al. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J Biol Chem. 2011;286:18593–18601.
   PubMed Web of Science ®Google Scholar
• Kheir V, Dirani A, Halfon M, et al. Multimodal imaging of retinal pigment epithelial detachments in patients with C3 glomerulopathy: case report and review of the literature. BMC Ophthalmol. 2017; 17:207.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Iartchouk O, Chin K, et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet. 2011;43:1232–1236.
   PubMed Web of Science ®Google Scholar
• Atkinson JP, Goodship TH. Complement factor H and the hemolytic uremic syndrome. J Exp Med. 2007;204:1245–1248.
   PubMed Web of Science ®Google Scholar
• Wright AF. A rare variant in CFH directly links age-related macular degeneration with rare glomerular nephropathies. Nat Genet. 2011;43:1176–1177.
   PubMed Web of Science ®Google Scholar
• Yehoshua Z, de Amorim Garcia Filho CA, Rp N, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121:693–701.
   PubMed Web of Science ®Google Scholar
• Cashman SM, Ramo K, Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates Choroidal Neovascularization in a model of age related macular degeneration. PLoS ONE. 2011;6:e19078.
   PubMed Web of Science ®Google Scholar
• Ramo K, Cashman SM, Kumar-Singh R. Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE. Invest Ophthalmol Vis Sci. 2008;49:4126–4136.
   PubMed Web of Science ®Google Scholar
• Hemera Biosciences. Available at: http://www.hemerabiosciences.com/.
   Google Scholar
• MeiraGTx. Available at: http://meiragtxcom/pipeline/.
   Google Scholar
• Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology. 2003;110:1151–1158.
   PubMed Web of Science ®Google Scholar
• Fishman GA, Farber M, Patel BS, et al. Visual acuity loss in patients with Stargardt’s macular dystrophy. Ophthalmology. 1987;94:809–814.
   PubMed Web of Science ®Google Scholar
• Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med. 2002;33:611–619.
   PubMed Web of Science ®Google Scholar
• Gray DA, Woulfe J. Lipofuscin and aging: a matter of toxic waste. Sci Aging Knowl Environ. 2005;2005:re1.
   PubMedGoogle Scholar
• Katz ML, Robison WG Jr. What is lipofuscin? Defining characteristics and differentiation from other autofluorescent lysosomal storage bodies. Arch Gerontol Geriatr. 2002;34:169–184.
   PubMed Web of Science ®Google Scholar
• de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355:1474–1485.
   PubMed Web of Science ®Google Scholar
• Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80:595–606.
   PubMed Web of Science ®Google Scholar
• Gomes NL, Greenstein VC, Carlson JN, et al. A comparison of fundus autofluorescence and retinal structure in patients with Stargardt disease. Invest Ophthalmol Vis Sci. 2009;50:3953–3959.
   PubMed Web of Science ®Google Scholar
• Lee W, Noupuu K, Oll M, et al. The external limiting membrane in early-onset Stargardt disease. Invest Ophthalmol Vis Sci. 2014;55:6139–6149.
   PubMed Web of Science ®Google Scholar
• Weng J, Mata NL, Azarian SM, et al. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt’s disease from the phenotype in abcr knockout mice. Cell. 1999;98:13–23.
   PubMed Web of Science ®Google Scholar
• Sparrow JR, Fishkin N, Zhou J, et al. A2E, a byproduct of the visual cycle. Vision Res. 2003;43:2983–2990.
   PubMed Web of Science ®Google Scholar
• Lamb LE, Simon JD. A2E: a component of ocular lipofuscin. Photochem Photobiol. 2004;79:127–136.
   PubMed Web of Science ®Google Scholar
• Suter M, Reme C, Grimm C, et al. Age-related macular degeneration. The lipofusion component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J Biol Chem. 2000;275:39625–39630.
   PubMed Web of Science ®Google Scholar
• Finnemann SC, Leung LW, Rodriguez-Boulan E. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2002;99:3842–3847.
   PubMed Web of Science ®Google Scholar
• Pilgrim MG, Lengyel I, Lanzirotti A, et al. Subretinal pigment epithelial deposition of drusen components including hydroxyapatite in a primary cell culture model. Invest Ophthalmol Vis Sci. 2017;58:708–719.
   PubMed Web of Science ®Google Scholar
• Zhou J, Kim SR, Westlund BS, et al. Complement activation by bisretinoid constituents of RPE lipofuscin. Invest Ophthalmol Vis Sci. 2009;50:1392–1399.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jang YP, Kim SR, et al. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2006;103:16182–16187.
   PubMed Web of Science ®Google Scholar
• Lenis TL, Sarfare S, Jiang Z, et al. Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease. Proc Natl Acad Sci U S A. 2017;114:3987–3992.
   PubMed Web of Science ®Google Scholar
• Csaky KG. Complement C5 inhibition as a potential treatment for autosomal recessive stargardt disease (STGD1): design of a clinical trial assessing a novel treatment and primary outcome measure. Invest Ophthalmol Vis Sci. 2018;59:1569.
   Web of Science ®Google Scholar
• C CLG561 proof-of-concept study as a monotherapy and in combination with LFG316 in subjects with Geographic Atrophy (GA). Available from https://clinicaltrials.gov/ct2/show/NCT02515942
   Google Scholar
• Kong X, Strauss RW, Cideciyan AV, et al. Visual acuity change over 12 months in the prospective progression of atrophy secondary to stargardt disease (progstar) study: progStar report number 6. Ophthalmology. 2017;124:1640–1651.
   PubMed Web of Science ®Google Scholar
• Schonbach EM, Wolfson Y, Strauss RW, et al. Macular sensitivity measured with microperimetry in stargardt disease in the progression of atrophy secondary to stargardt disease (progstar) study: report no7. JAMA Ophthalmol. 2017;135:696–703.
   PubMed Web of Science ®Google Scholar
• Strauss RW, Munoz B, Ho A, et al. Progression of Stargardt disease as determined by fundus autofluorescence in the retrospective progression of stargardt disease study (ProgStar report no 9). JAMA Ophthalmol. 2017;135:1232–1241.
   PubMed Web of Science ®Google Scholar
• Strauss RW, Munoz B, Ho A, et al. Incidence of atrophic lesions in stargardt disease in the progression of atrophy secondary to stargardt disease (progstar) study: report no 5. JAMA Ophthalmol. 2017;135:687–695.
   PubMed Web of Science ®Google Scholar